Do planned organs-at-risk DVHs represent reality in cervix HDR brachytherapy? A time-based anatomical study

Brachytherapy ◽  
2008 ◽  
Vol 7 (2) ◽  
pp. 124
Author(s):  
Subhakar Mutyala ◽  
Raquibul Hannan ◽  
Nitika Thawani ◽  
Matt Biagioli ◽  
Amella Pollack ◽  
...  
2016 ◽  
Vol 2016 ◽  
pp. 1-13 ◽  
Author(s):  
M. Sean Peach ◽  
Daniel M. Trifiletti ◽  
Bruce Libby

Prostate cancer is the most common malignancy found in North American and European men and the second most common cause of cancer related death. Since the practice of PSA screening has become common the disease is most often found early and can have a long indolent course. Current definitive therapy treats the whole gland but has considerable long-term side effects. Focal therapies may be able to target the cancer while decreasing dose to organs at risk. Our objective was to determine if focal prostate brachytherapy could meet target objectives while permitting a decrease in dose to organs at risk in a way that would allow future salvage treatments. Further, we wanted to determine if focal treatment results in less toxicity. Utilizing the Medline repository, dosimetric papers comparing whole gland to partial gland brachytherapy and clinical papers that reported toxicity of focal brachytherapy were selected. A total of 9 dosimetric and 6 clinical papers met these inclusion criteria. Together, these manuscripts suggest that focal brachytherapy may be employed to decrease dose to organs at risk with decreased toxicity. Of current technology, image-guided HDR brachytherapy using MRI registered to transrectal ultrasound offers the flexibility and efficiency to achieve such focal treatments.


2014 ◽  
Vol 132 (1) ◽  
pp. 93-97 ◽  
Author(s):  
Agnieszka Zolciak-Siwinska ◽  
Michal Bijok ◽  
Joanna Jonska-Gmyrek ◽  
Maria Kawczynska ◽  
Lucyna Kepka ◽  
...  

2014 ◽  
Vol 41 (6Part21) ◽  
pp. 374-374
Author(s):  
M Nair ◽  
C Li ◽  
M White ◽  
J Davis

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17006-e17006
Author(s):  
Jyoti Poddar ◽  
Ashutosh Das Sharma ◽  
U Suryanarayan K ◽  
Sonal Patel Shah ◽  
Ankita Parikh

e17006 Background: External beam radiotherapy combined with intracavitary brachytherapy is the standard of care in Carcinoma cervix. Due to its characteristics of rapid dose fall off, brachytherapy limits the toxicity to organs at risk while escalating radiation dose to target. Still, the organs near the radioactive source are at risk of considerable exposure, toxicity and post treatment morbidity. Alteration of bladder volume, alters the relative anatomy of uterus, rectum, sigmoid colon causing changes in the radiation dose to these organs. Methods: Aim:To correlate between the bladder volume and its effects on the dose received by bladder, rectum and sigmoid colon in volume based HDR brachytherapy in carcinoma cervix.30 patients (78 Intracavitary Brachytherapy applications) of Carcinoma Cervix (FIGO stage II-III) treated with EBRT followed by volume based HDR brachytherapy at our institute between July 2014 to Jan 2016 were studied. Bladder volume data was tabulated into five groups according to increasing volume of bladder. It was correlated with D2cc dose received by bladder, rectum and sigmoid colon. Results: Statistical Analysis Linear regression and correlation analysisof the HRCTV with dose to the bladder was 0.2 (.i.e HRCTV does not influence the bladder dose.) Pearson correlation of bladder volume and D2cc bladder and D2cc rectum was positive for all groups and for sigmoid D2cc was positive for group B and negative for all other groups. P value = 0.064 Conclusions: Keeping the bladder volume low (<130 cc) during brachytherapy would reduce the dose to bladder and rectum and the probability of late bladder and rectal toxicity reduces. [Table: see text]


Brachytherapy ◽  
2014 ◽  
Vol 13 ◽  
pp. S102
Author(s):  
Jennifer Barclay ◽  
Arnold Pompoš ◽  
Xuejun Gu ◽  
Kevin Albuquerque

Sign in / Sign up

Export Citation Format

Share Document